Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website
HSRD Conference Logo



2017 HSR&D/QUERI National Conference Abstract

Printable View

4003 — Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in VHA Heart Failure Patients by Race

Lead/Presenter: Boback Ziaeian, COIN - Los Angeles
All Authors: Ziaeian B (VA GLA) Fonarow GC (UCLA) Heidenreich PA (VA Palo Alto)

Objectives:
Among African American patients with heart failure (HF) with reduced ejection fraction (HFrEF), the combination of hydralazine and isosorbide dinatrate (H-ISDN) in addition to usual care was found to improve quality of life, lower HF hospitalization and mortality rates in the A-HEFT randomized control trial. Few studies have evaluated the effectiveness in a real-world setting. Here we observe the benefits of therapy in the VA HFrEF population.

Methods:
VA patients with a primary HF admission between 2007 to 2013 were screened for inclusion in an observational cohort. Inclusion criteria included African American race, left ventricular ejection fraction < 40%, and received regular medications through the VA pharmacy. Patients were excluded if they had contraindications to receiving H-ISDN, a creatinine greater 2.0, or intolerance to angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). Hazard ratios (HR) were calculated for patients who received H-ISDN 6 months prior to admission compared to those that did not receive H-ISDN using inverse probability weighting of propensity scores and a time to death analysis with 18 months of follow-up. Propensity scores were generated using patient characteristics, vitals, lab values, and hospital characteristics.

Results:
The final cohort included 5,168 African American HF patients (age 65.19) with 15.2% treated with H-ISDN prior to index admission. After 18 months of follow-up from index admission, there were 1,275 reported deaths (24.7%). The unadjusted HR was 0.88, (p = 0.11), adjusted HR using inverse probability weighting of propensity scores were 0.85, (p = 0.006). Adjusted mortality at 18 months was 22.1% for H-ISDN treatment and 25.2% for untreated (p = 0.009).

Implications:
H-ISDN remains underutilized in African American patients with HFrEF for unclear reasons. In this observational cohort, we find a significant mortality advantage associated with H-ISDN use in African American HFrEF patients at 18 months when adjusting for patient and hospital factors using an inverse probability weighted propensity score model.

Impacts:
H-ISDN is under-utilized for African American HFrEF patients. We observe evidence for a sustained benefit associated with usage.